Abbott CEO aims for more than one million Libre users by 2019

Topping estimates on Wall Street, Abbott (NYSE:ABT) shares climbed yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre.